OGC
UBX

One68 Global Capital’s Unity Biotechnology UBX Stock Holding History

One68 Global Capital’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,072
Closed -$149K – 52
2019
Q4 		$149K Buy
+2,072
New +$146K 0.32% 70

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

One68 Global Capital's UBX Position: Q1 2020 in Review

One68 Global Capital sold out of Unity Biotechnology (UBX) in Q1 2020, closing a stake of 2,072 shares — an estimated $149K sold.

One68 Global Capital first reported a position in UBX in Q4 2019 and held it in 1 quarter. The position peaked at $149K in Q4 2019. 74 funds tracked by Wall St. Rank hold UBX as of Q1 2020.

  • One68 Global Capital reported no remaining Unity Biotechnology position as of Q1 2020 after selling out during the quarter.
  • One68 Global Capital sold 2,072 Unity Biotechnology shares in Q1 2020, an estimated $149K.
  • One68 Global Capital first reported a position in Unity Biotechnology in Q4 2019 and held it in 1 quarter.
  • One68 Global Capital's Unity Biotechnology position peaked at $149K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2020.

Based on One68 Global Capital's 13F filing for Q1 2020, filed 15 May 2020.